Company Profile

Data2Discovery Inc
Profile last edited on: 2/7/18      CAGE: 75EH3      UEI: VBPZQGMV2DN5

Business Identifier: Advanced semantic technologies to find/interpret associations in integrated data sets
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

901 E 10th Street
Bloomington, IN 47408
   (636) 448-2934
Location: Single
Congr. District: 09
County: Monroe

Public Profile

Data2Discovery transforms organizations by applying Machine Learning and Artificial Intelligence (AI) methodologies to the client's most important business challenges. The firm is pioneering a transformative new big data approach to understand and treat disease by connecting together data in ways never tried before creating new keys to effective disease treatment. By linking diverse datasets from molecule to genome to patient, and applying machine learning patent-pending algorithms, we uncover hidden connections and new insights. Bringing together experts in drug discovery, medical research, AI/machine learning, data science, and healthcare IT, Data2Discovery uses an advanced stack of scalable graph technologies, public and proprietary data sources, patent-pending AI and machine learning, graph mining capabilities, and our extensive experience in linking and mapping data to address customers biggest problems. Knowledge creation and association mining via AI and graphs enables the capability to associate related connections and entities with a comprehensive knowledge base. AI using graphs are remarkable not just because of the possibilities they engender, but also because of their practicality. The confluence of knowledge via machine learning, graph databases, and big data provide the ability to see links between objects, and quantifies the likelihood of their occurrence. This is impossible to achieve efficiently with legacy relational database technologies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NSF $1,503,520
Project Title: Semantic Link Association Prediction for Phenotypic Drug Discovery

Key People / Management

  David J Wild -- CEO

  Ying Ding -- echnology Director

  John Hill -- COO

  Randy Kerber

  Kyle Stirling -- VP of Technology Resource Management

Company News

There are no news available.